NEW YORK (360Dx) – Australian proteomics firm Proteomics International Laboratories said today it has licensed US sales of its PromarkerD test for diabetic kidney disease to PrismHealthDx (PHDx).
According to Proteomics International, Austin, Texas-based PHDx will roll out a national launch of the test, which uses mass spectrometry to measure blood-based proteins to predict diabetes patients' risk of developing diabetic kidney disease. PHDx will offer the test as a laboratory-developed test out of its CLIA facilities.
Financial and other terms of the agreement were not disclosed.
"We are very excited to launch this product nationally across the USA," Jim Canfield, president and CEO of PHDx, said in a statement. "It will save lives and improve the quality of life for diabetes sufferers, all while reducing the cost to the healthcare system."
"Regular testing and early diagnosis of diabetic kidney disease with PromarkerD can help millions of people avoid costly and invasive dialysis treatment or a kidney transplant," Richard Lipscombe, managing director of Proteomics International, said in a statement.
Proteomics International launched PromarkerD in the Dominican Republic in March 2018 and now aims to commercialize the test in countries including Mexico, Japan, Australia, China, and various European countries.